Ryan Potts
@pottslab
Followers
2K
Following
2K
Media
104
Statuses
759
VP & Head of Induced Proximity Platform, @Amgen | Scientist | Father
Thousand Oaks, CA
Joined January 2014
What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. #mycompnay.
science.org
Biology is governed by macromolecular interactions, perturbation of which often lies at the heart of disease. Most therapeutic drugs, whether they are small molecules or biologics, exert their...
7
32
133
RT @PPMC_UAB: Great to see our two in-house developed kinetic stabilizers, Tolcapone and PITB, against transthyretin amyloidoses cited as e….
science.org
Biology is governed by macromolecular interactions, perturbation of which often lies at the heart of disease. Most therapeutic drugs, whether they are small molecules or biologics, exert their...
0
4
0
RT @MaverickNY: Talking of @amgen they also have cool LYMTACs: chimeric small molecules repurpose lysosomal membrane proteins for target pr….
nature.com
Nature Communications - LYMTACs are heterobifunctional small molecules that take advantage of lysosomal membrane proteins to degrade membrane targets via relocalization and lysosomal degradation,...
0
6
0
RT @afederation: Degradation without E3s? . Cool approach here - molecules that drag membrane proteins into lysosomes for degradation. Migh….
0
1
0
Check out how we repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @nalawansha and team! #mycompany .
🚨New @biorxivpreprint from the @Amgen Induced Proximity group. Here we introduce LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation. 🧵
0
5
31
RT @jaybradner: From decoding the genome’s “dark matter” to designing next-gen medicines, @HowardYChang is the ideal leader for @Amgen Rese….
0
2
0
RT @LabSpiegelman: The passing Of Dave Mangelsdorf is a terrible loss for his family, friends and the science world. Davo will never be for….
0
28
0
Ray Deshaies has a new piece in Nature Reviews Drug Discovery on how multispecific drugs are reshaping pharmacology. During his time at @Amgen, Ray challenged us to rethink what molecules could do, especially with induced proximity. #MyCompany .
nature.com
Nature Reviews Drug Discovery - Multispecific drugs are designed to engage two or more entities to exert their pharmacological effect. This Perspective discusses how a new wave of FDA-approved...
0
15
57
RT @AMELIA53034756: @pottslab Amazing opportunity for recent STEM grads! A paid 2-year fellowship at Amgen with real research, publication….
0
1
0
🎓 Recent STEM grad? Jump-start your PhD journey with Amgen’s new 2-yr paid Postbaccalaureate Research Fellowship in Thousand Oaks! Work with world-class scientists, publish your findings, and make a real impact for patients. Apply by July 15 ➡️
1
1
24
RT @DanNomura: Happy to present our latest paper with @pottslab & @Amgen in @J_A_C_S by co-first authors @C_M_Zammit & Cory Nadel on the d….
0
21
0
Very cool!.
Molecular surface mimicry enables CRBN to target G3BP2 for degradation #biorxiv_molbio.
0
0
2
DEL is accelerating our Induced Proximity Platform—helping us discover small molecules that rewire cellular processes and bind challenging targets. A powerful example of DNA driving therapeutic innovation. #DNADay #MyCompany.
Our DNA-Encoded Library (DEL) platform 🧬 is accelerating drug discovery by rapidly identifying molecules that have the potential to become therapies. This #DNADay, discover how we’re using DNA to advance therapeutics for those in need 🔗:.
0
1
32
RT @biorxiv_biochem: Proteome-Wide Discovery of Degradable Proteins Using Bifunctional Molecules #biorxiv_biochem.
biorxiv.org
Targeted protein degradation (TPD) is an emergent therapeutic strategy with the potential to circumvent challenges associated with targets unamenable to conventional pharmacological inhibition. Among...
0
6
0
RT @biorxiv_molbio: Bacterial ubiquitin ligase engineered for small molecule and protein target identification #bio….
biorxiv.org
The Legionella SidE effectors ubiquitinate host proteins independently of the canonical E1-E2 cascade. Here we engineer the SidE ligases to develop a modular proximity ligation approach for the...
0
2
0
RT @CellChemBiol: .@pottslab @Amgen demonstrate proof-of-concept of disease-specific targeted degradation by redirecting virally encoded E3….
cell.com
The therapeutic application of targeted protein degradation (TPD) is limited by target degradation in healthy cells. Mangano et al. demonstrate proof-of-concept of truly disease-specific TPD by...
0
9
0
RT @HartungIngo: Congrats to the teams @Amgen & @PlexiumTx for an impressive piece of work. After work by Novartis now providing additional….
0
3
0